(IN BRIEF) Nokia has appointed Kristen Pressner as Chief People Officer and member of the Group Leadership Team, effective May 2026. With over 30 years of HR and leadership experience at Roche and Texas Instruments, Pressner will lead Nokia’s global … Read the full press release
Posted in Business, Finland, Management, News, Technology, Telecom
Tagged 5G, AI, AI empowerment, Chief People Officer, connectivity, Finland, global technology, HR transformation, Justin Hotard, Kristen Pressner, leadership appointment, next-generation networks, Nokia, Nokia appoints Kristen Pressner as Chief People Officer to drive global culture and AI-era transformation, organizational culture, Roche, Texas Instruments, workforce innovation
(IN BRIEF) Roche announced that its Phase III INShore trial evaluating Gazyva/Gazyvaro (obinutuzumab) in children and young adults with idiopathic nephrotic syndrome met its primary endpoint, showing superior sustained remission rates at one year compared to mycophenolate mofetil (MMF). The … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged B cell targeting, Basel, Chronic kidney disease, corticosteroids, EMA, FDA, Gazyva, Gazyva/Gazyvaro Demonstrates Superior Sustained Remission in Children and Young Adults With Idiopathic Nephrotic Syndrome, Gazyvaro, idiopathic nephrotic syndrome, immune-mediated kidney diseases, INS, INShore study, Levi Garraway, lupus nephritis, NOBILITY study, obinutuzumab, pediatric nephrology, phase III clinical trial, proteinuria, REGENCY study, renal disease, Roche, Roche Announces Positive Phase III INShore Results for Gazyva/Gazyvaro in Children and Young Adults With Idiopathic Nephrotic Syndrome, sustained remission, targeted therapy
(IN BRIEF) Roche reported groundbreaking phase III IMvigor011 results showing that Tecentriq (atezolizumab) significantly improved overall and disease-free survival in muscle-invasive bladder cancer using a ctDNA-guided treatment approach. Patients receiving Tecentriq experienced a 41% lower risk of death and a … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged adjuvant therapy, atezolizumab, bladder cancer, Cancer Immunotherapy, ctDNA, disease-free survival, ESMO Congress 2025, IMvigor011, Levi Garraway, molecular residual disease, MRD testing, muscle-invasive bladder cancer, Natera, oncology research, precision oncology, Roche, Roche Advances Personalized Oncology with Positive Phase III Tecentriq Results in ctDNA-Directed Bladder Cancer Treatment, Roche’s Tecentriq Shows 41% Survival Benefit in Landmark ctDNA-Guided Bladder Cancer Study, Signatera, survival benefit, TECENTRIQ, Thomas Powles
(IN BRIEF) Roche has received FDA approval for Gazyva/Gazyvaro (obinutuzumab) as a treatment for adult patients with active lupus nephritis, supported by data from the NOBILITY and REGENCY trials that showed significantly improved renal response compared with standard therapy. The … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged anti-CD20 monoclonal antibody, autoimmune disease, autoimmune therapy, biopharmaceuticals, CHMP, European Medicines Agency, FDA approval, Gazyva, Gazyva/Gazyvaro Approved by FDA as First Anti-CD20 Therapy to Achieve Complete Renal Response in Lupus Nephritis, Gazyvaro, kidney disease, Levi Garraway, Louise Vetter, Lupus Foundation of America, lupus nephritis, nephrology, NOBILITY trial, obinutuzumab, REGENCY trial, renal response, Roche, Roche Basel, Roche Strengthens Autoimmune Portfolio with FDA Approval of Gazyva/Gazyvaro for Lupus Nephritis Treatment, systemic lupus erythematosus
(IN BRIEF) Roche presented new data at ECTRIMS 2025 confirming that OCREVUS provides sustained protection against disability progression and maintains a consistent safety profile across multiple MS populations, including adults with advanced PPMS, children with RRMS, and women who are … Read the full press release
Posted in Healthcare, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged BTK inhibitor, disability progression, ECTRIMS 2025, fenebrutinib, FENhance, FENopta, FENtrepid, infant immunity, Levi Garraway, MINORE, MS, multiple sclerosis, neurofilament light chain, OCARINA II, ocrelizumab, OCREVUS, OPERETTA, ORATORIO-HAND, paediatric MS, PPMS, pregnancy outcomes, RMS, Roche, Roche presents late-breaking MS data including OCREVUS impact in pregnancy and two-year fenebrutinib Phase II outcomes, Roche showcases new OCREVUS and fenebrutinib data at ECTRIMS 2025 highlighting long-term efficacy and safety in MS, RRMS, SOPRANINO, Stephen L Hauser
(IN BRIEF) Roche has announced new data at the Euretina Congress in Paris from its AVONELLE-X and SALWEEN studies of Vabysmo (faricimab), confirming the therapy’s strong long-term outcomes for patients with retinal diseases. The AVONELLE-X study, the largest long-term extension … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged AVONELLE-X, bispecific antibody, diabetic macular edema, DME, durability, Euretina Congress, extended dosing, faricimab, Levi Garraway, long-term efficacy, LUCERNE, nAMD, neovascular age-related macular degeneration, ophthalmology, PCV, polypoidal choroidal vasculopathy, retinal vein occlusion, Roche, RVO, SALWEEN, TENAYA, Vabysmo, vision loss
(IN BRIEF) Roche’s ongoing Phase Ib/IIa Brainshuttle™ AD study of trontinemab shows that 91 percent of participants reach amyloid PET negativity, with ARIA‑E rates under 5 percent. The company has outlined Phase III TRONTIER 1 and 2 trials in early symptomatic Alzheimer’s for 2025, plus a planned … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Alzheimer’s Association International Conference, amyloid plaques, amyloid‑beta monoclonal antibody, ARIA‑E, blood‑based biomarker, blood‑brain barrier, Brainshuttle, centiloids, clinical dementia rating sum of boxes, cognitive decline, diagnostics, early diagnosis, Elecsys pTau217, Levi Garraway, Matt Sause, PET negativity, Phase Ib/IIa, Phase III TRONTIER 1, Phase III TRONTIER 2, preclinical Alzheimer’s, pTau181, pTau217/Ab42 ratio, Roche, sustainability of clinical trials, TRAVELLER, trontinemab
(IN BRIEF) Roche has revealed that Dr. Hans Clevers, Head of Pharma Research and Early Development and board member since 2019, will retire from his pRED role at the end of August, though he will continue leading the Institute of … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged appointment, Barbara Schädler, Board of Directors, corporate executive committee, COVID-19, Group Communications, Hans Clevers, Institute of Human Biology, Johannes Clevers, ledership, Pharma Research and Early Development, pRED, retirement, Roche, succession planning, Thomas Schinecker
(IN BRIEF) Roche presented positive phase I/II data for NXT007, its Chugai-engineered bispecific antibody for haemophilia A, at the 2025 ISTH Congress. In the NXTAGE study’s highest-dose cohorts (B-3 and B-4), none of the 30 participants experienced bleeds requiring treatment, … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged bispecific antibody, Chugai, clinical development, emicizumab, global supply chain, Haemophilia A, haemostatic normalisation, Hemlibra, ISTH Congress 2025, Levi Garraway, NXT007, NXTAGE study, phase I/II data, Roche, subcutaneous dosing, thromboembolic events
(IN BRIEF) Roche announced the European Commission’s approval of a label extension for Evrysdi® (risdiplam) to include a new 5mg tablet, offering a room-temperature stable alternative to the original oral solution for individuals with spinal muscular atrophy (SMA). The tablet, … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Switzerland, Technology
Tagged 5mg tablet, bioequivalence, clinical development, clinical study, disease-modifying treatment, European Commission, Evrysdi, family caregivers, label extension, Nicole Gusset, non-invasive treatment, PTC Therapeutics, risdiplam, Roche, SMA, SMA Europe, SMA Foundation, SMA patients, SMN protein, spinal muscular atrophy, treatment flexibility
(IN BRIEF) Roche presented promising 96-week data from the Phase II FENopta study, showing that its investigational drug, fenebrutinib, significantly reduced relapse rates and prevented disability progression in patients with relapsing multiple sclerosis (RMS). The study revealed an annualized relapse … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Bruton’s tyrosine kinase, BTK inhibitor, clinical data, clinical research, clinical trial, data, disability, disability progression, fenebrutinib, FENopta, Levi Garraway, multiple sclerosis, Phase II, relapse rates, relapsing multiple sclerosis, RMS, Roche, treatment
(IN BRIEF) The Vienna Stock Exchange has expanded its global market offering by allowing the trading of all stocks in the Swiss Market Index (SMI), which includes leading companies like Nestlé, Novartis, Roche, and UBS. This follows the Swiss Federal … Read the full press release
(IN BRIEF) Roche has launched a CE-marked Chest Pain Triage algorithm developed with Universitätsklinikum Heidelberg to improve emergency diagnosis of chest pain. Integrated into the navify® Algorithm Suite, the tool uses high-sensitivity cardiac troponin testing and ESC guidelines to support … Read the full press release
Posted in Artificial Intelligence (AI), Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged acute coronary syndrome, AI in healthcare, cardiac diagnostics, cardiovascular disease, CE-marked IVD, Chest Pain Triage Algorithm, digital diagnostics, digital health, EHR integration, emergency department, ESC guidelines, Healthcare Innovation, high-sensitivity troponin, hospital workflow optimization, Matt Sause, medical device, navify Algorithm Suite, patient triage, Roche, Universitätsklinikum Heidelberg
(IN BRIEF) Roche presented new data at the AD/PD 2025 International Conference demonstrating that trontinemab, in its Phase Ib/IIa Brainshuttle™ AD study, achieves rapid and dose-dependent reductions of amyloid plaques in the brain, with significant biomarker improvements observed in fluid … Read the full press release
Posted in Austria, Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Media, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged AD/PD 2025 International Conference, Alzheimer’s disease, amyloid plaques, ARIA-E, biomarkers, Brainshuttle AD study, cognitive impairment, diagnostic solutions, dose-dependent reduction, Elecsys pTau181 plasma test, Levi Garraway, neurogranin, Phase Ib/IIa study, Phase III programme, pTau181, pTau217, Roche, total tau, trontinemab
(IN BRIEF) Roche announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston, establishing a hub that will drive breakthroughs in Cardiovascular, Renal, and Metabolism research while also leveraging data science and AI … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged AI, Alan Garber, Allston, Boston, cardiovascular, data science, drug discovery, Genentech, Harvard Enterprise Research Campus, Healthcare Innovation, Manu Chakravarthy, Maura Healey, METABOLISM, Michelle Wu, Mixed-Use Campus, partnership, Public Private Partnership, Renal, research and development, Roche, Roche Genentech Innovation Center Boston, Thomas Schinecker, USD11 Billion Investment
(IN BRIEF) Researchers at the Institute of Cancer Research in London have identified genetic markers that predict a significant survival benefit from combining ipatasertib with abiraterone in treating metastatic castration-resistant prostate cancer. In the phase III IPATential150 trial, patients whose … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged abiraterone, AKT inhibitor, biomarkers, clinical trial, genetic markers, Institute of Cancer Research London, ipatasertib, IPATential150 trial, metastatic castration-resistant prostate cancer mCRPC, overall survival, personalized medicine, PIK3CA/AKT1/PTEN pathway, Professor Johann de Bono, PTEN gene, Roche, sequencing techniques, synthetic lethality, targeted therapy, UK patients
(IN BRIEF) UBS Group AG has nominated Renata Jungo Brüngger and Lila Tretikov for election to its Board of Directors at the Annual General Meeting on 10 April 2025. Jungo Brüngger brings expertise in governance, sustainability, and legal affairs from … Read the full press release
Posted in Banks, Business, Financial, Industrial, Investment, Management, News, Switzerland
Tagged Annual General Meeting, appointment, artificial intelligence, Audit Committee, Board of Directors, Claudia Böckstiegel, Colm Kelleher, Daimler Truck Holding AG, ENGIE, Governance, Governance and Nominating Committee, leadership, Lila Tretikov, Mercedes-Benz Group AG, Microsoft, Munich Re, Nathalie Rachou, New Enterprise Associates, Renata Jungo Brüngger, Risk Committee, Roche, sustainability, technology-driven business transformation, UBS
(IN BRIEF) The Conference Forum has announced the 9th annual Patients as Partners® Europe event, scheduled for May 20-21, 2025, at the Royal National Hotel in London. This event offers a platform for pharma R&D and patient advocacy to discuss … Read the full press release
Posted in France, Healthcare, Marketing, Pharma & Biotech, Science, Switzerland, United Kingdom
Tagged Alfred Samuels, AstraZeneca, Azafaros, Beyza Klein, Biotech, Biotechnology Conference, Boehringer Ingelheim, Bre Bugbee-Barrett, Catherine Coulouvrat MD, Chiesi Farmaceutici SpA, clinical development, clinical operations, clinical research, clinical research enterprise, clinical trial, clinical trials, Conference Forum, decentralized clinical trials, Gisela Linthorst, GSK, Harry Verbunt, HTA/Regulatory requirements, Johnson & Johnson Innovative Medicine, Lea-Isabelle Proulx PhD, life post-cancer diagnosis, Marisa Minetti, Medicine Development, Patient Advocacy, patient engagement, patient engagement in drug development, patient experience, Patient Recruitment, Patient Retention, Patients as Partners, Patients as Partners Europe, Peter DiBiaso, pharma, Pharmaceutical Conference, Regeneron, research and development, Roche, Royal National Hotel, Sanofi, Temi Olonisakin MD, The Conference Forum, Valerie Bowling
(IN BRIEF) The University of St.Gallen and ETH Zurich have partnered to establish the “ETH-HSG Manufacturing Alliance,” aimed at boosting the competitiveness of Swiss industry and nurturing young talent. The alliance is supported by 13 leading industrial partners, including Roche, … Read the full press release
Posted in Business, Education, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged artificial intelligence, artnership, Circle of Scholars, doctoral students, Endress+Hauser Flowtec, ETH Zurich, ETH-HSG Manufacturing Alliance, Givaudan, Johnson & Johnson Innovative Medicine, Leila Schwery, Lindt & Sprüngli, manufacturing innovation, Nestlé, Novartis, Operational Excellence, Peter Hagmann, Roche, Schindler, Schneider Electric, SFS Group, SHL Medical, sustainable business practices, Swiss industry, Swiss Manufacturing Survey 2024, Takeda, talent development, University of St.Gallen, VAT Group
(IN BRIEF) Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HER2-ultralow status in HR-positive, HER2-negative metastatic breast cancer patients. This new approval offers a potential treatment … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged breast cancer, DESTINY-Breast06 trial, diagnostic solutions, Enhertu, FDA, FDA approval, HER2-Low, HER2-targeted therapy, HER2-Ultralow, HR-positive, metastatic breast cancer, PATHWAY HER2, Personalized Treatment, Roche, treatment options
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?